Skip to main contentSkip to privacy choices

Clinical Safety Consultancy wording revision · Preview only

HealthTech Governance & Clinical Safety

Digital Clinical Safety Consultancy: DCB0129 & DCB0160

DCB0129 consultancy for digital health suppliers, and DCB0160 consultancy for NHS organisations. DCB0129 applies to manufacturers during software development; DCB0160 applies when an NHS organisation deploys the system.

We assess evidence gaps, develop hazard logs and safety cases, and support deployment within an agreed scope, so you can show NHS procurement teams how you comply with DCB0129 or DCB0160.

The applicable standard depends on your system, role and intended use. Appointed CSO provision is included only where agreed in writing; named or retained CSO services are described on Clinical Safety Officer Services.

Clinical safety consultancy for digital health suppliers, NHS organisations and other health and care providers — from early design through deployment, use and change. Independent assurance is separately scoped and subject to conflict checks.

View relevant evidence — View Relevant Evidence

When this service fits

When this service fits

  • You are building or changing a health IT system

  • You are deploying digital technology into care pathways

  • You build software-as-a-medical-device or AI-enabled health technology

  • You are adapting an overseas product for the NHS and UK market

  • You are preparing for DTAC, procurement, pilot use or wider adoption

  • You are addressing clinical safety findings, incidents, audit actions or major system change

The service

NHS DCB0129 and DCB0160 requirements

DCB0129 covers clinical risk management in the manufacture of health IT. DCB0160 covers deployment and use. These information standards sit within the Health and Social Care Act 2012 framework.

Applicability depends on the system, its intended use, the organisation's role and the deployment context. Not every supplier is subject to both standards. Supplier evidence does not by itself meet a deploying organisation's responsibilities.

We review the safety context, evidence gaps, hazards, controls and governance within an agreed scope. DTAC includes clinical safety, but a completed DTAC form does not replace the applicable standard or the deploying organisation's duties.

NHS England clinical safety assurance guidance

For a named appointment or support alongside your existing CSO, see Outsourced Clinical Safety Officer Services. For named appointments, suitability, current eligibility and availability are checked; mandate, responsibilities and terms are agreed before engagement. Your organisation retains accountability and risk-acceptance, release and deployment decisions through its authorised governance arrangements.

Two related services

Which service fits?

Choose Clinical Safety Officer Services for a named appointment or ongoing support for an existing CSO. Choose Clinical Safety Consultancy for defined-scope assessment, evidence development or implementation support. Appointment provision can form part of an engagement where expressly agreed.

The work · You are hereClinical Safety ConsultancyAssessing gaps, establishing or improving clinical risk management, facilitating hazard analysis and developing or reviewing agreed safety evidence.
Appointment or ongoing supportClinical Safety Officer ServicesA named CSO within an agreed mandate, or additional specialist capacity alongside your existing CSO. Client accountability and decision rights remain explicit.Explore this service

DCB0129

Manufacturer responsibilities

Applies to organisations manufacturing health IT systems: clinical risk management across development, release, maintenance and change of the product.

DCB0160

Deployment and use responsibilities

Applies to health and care organisations deploying and using those systems: local configuration, workflows, training and operational change.

Supplier evidence does not automatically satisfy a deploying organisation’s obligations. Applicability depends on the product, intended use and deployment context; the current published standards remain the operative requirements while NHS England’s review continues.

Already have an appointed CSO?

This service supports their clinical-risk-management processes, safety evidence, change reviews and governance reporting. Your appointed CSO retains clinical review and approval responsibilities.

Need a formally appointed CSO?

IG-Smart can provide a named senior clinical safety professional for an agreed CSO appointment. Suitability, current eligibility, availability, scope and responsibilities are checked before appointment. Your organisation retains accountability and authorised risk-acceptance and deployment decisions.

What changes for your organisation

Outcomes the service is built to deliver

  • Clinical safety governance diagnostic

    A focused review of the product or deployment context, intended use, clinical pathways, current evidence, responsibilities and major safety risks.

  • Hazard identification and assessment

    Facilitated workshops and evidence review to identify credible hazards, causes, controls, affected users and potential patient outcomes.

  • Clinical risk management planning

    A practical plan setting scope, method, roles, escalation, evidence needs, review points and approval duties.

  • Hazard log development and quality assurance

    Build or review a controlled log linking hazards to causes, controls, owners, residual risk and verification evidence.

  • Clinical safety case and report support

    A structured safety argument supported by evidence for the intended use, with assumptions, limitations, open issues and required actions.

  • Independent challenge and assurance

    Senior review of evidence quality, completeness and traceability before release, procurement, deployment or major change, where independence allows. No independent assurance over IG-Smart's own delivery or management work.

  • Ongoing governance and change control

    Support for monitoring, incident learning, periodic review, supplier coordination, decommissioning and major changes, where commissioned.

What is the engagement approach?

Five steps to defensible safety evidence

The agreed scope determines the activities, outputs and review arrangements.

  1. Define the safety context

    Confirm intended use, users, patient groups, clinical pathways, working environment, boundaries, dependencies and applicable responsibilities.

  2. Review current evidence

    Check plans, hazard logs, safety cases, tests, incident information, supplier evidence and governance records for completeness and consistency.

  3. Identify and evaluate hazards

    Use clinical and technical input to identify hazards, estimate risk and examine whether controls work and are evidenced.

  4. Strengthen governance and artefacts

    Address priority gaps, clarify ownership, improve traceability and prepare decision-ready safety documents.

  5. Assure and maintain

    Provide challenge, clinical approval support within the documented mandate and an agreed cadence for monitoring and change. Independent assurance is separately scoped and cannot cover IG-Smart's own delivery or management work.

Where CSO provision is expressly agreed, the named practitioner carries out the documented clinical duties. Authorised organisational decision-makers retain risk acceptance and release or deployment authority; consultancy alone does not create an appointment. Every engagement follows IG-Smart’s structured delivery approach: Assess → Build → Manage → Assure → Improve. Explore how we work

What each stage produces

  1. Define the safety context

    Agreed safety context and scope.

  2. Review current evidence

    Evidence review and gap findings.

  3. Identify and evaluate hazards

    Hazard workshop outputs and decision log.

  4. Strengthen governance and artefacts

    Hazard log, clinical risk management plan and safety case support.

  5. Assure and maintain

    Assessment or assurance report and agreed governance cadence.

2026 NHS England clinical safety standards review: supplier and trust readiness

NHS England’s national review does not itself replace the published DCB0129 and DCB0160 standards. Continue working to applicable current requirements, maintain version-controlled evidence and review the impact of official changes before altering a safety case or deployment decision. No transition date or procurement outcome is promised.

NHS England standards review

For product-level buyer evidence, see NHS DTAC readiness. DTAC’s clinical-safety area sits alongside, rather than replacing, applicable clinical risk management responsibilities.

What you receive

Clinical safety records and sample outputs

Core records include a Clinical Risk Management Plan, Hazard Log and Clinical Safety Case Report. Depending on scope, supporting outputs may include workshop records, safety requirements and control traceability, change-impact assessments, incident reviews, responsibility maps, action trackers and executive summaries. All examples, including the DTAC dashboard, use illustrative structures and data — not client documents, clinical approvals or proof of compliance. Exact outputs and formats are agreed in writing.

DTAC Readiness Dashboard · Pre-buyer reviewIllustrative data — not client data
Overall positionAmber — closing gaps
DTAC areas evidenced
3 / 5
▲ 1 this period
Open evidence gaps
6
▼ 3 vs last review
Responses challenged
18
▲ 12 resolved
Evidence owners assigned
9 / 10
▲ 2 this period

Evidence gaps by buyer impact

  • High1
  • Medium3
  • Low2

Evidence complete

68%

Overdue actions
2
Documents awaiting sign-off
3
Matters for escalation
1

Illustrative output

DTAC Readiness Dashboard

Readiness at a glance

A single view of readiness across the five DTAC areas, so gaps are closed before an NHS buyer reviews the form.

What it helps you see

  • Readiness across the five DTAC areas
  • Open evidence gaps by buyer impact
  • Readiness challenge progress
  • Evidence owners and sign-off status

Likely format

Dashboard / reporting view · Supporting registers and evidence records · Executive PDF summary where agreed

Clinical Risk Management Plan (CRMP)Illustrative structure
Clinical Risk Management Plan (CRMP)Illustrative data — not client data
Illustrative Clinical Risk Management Plan (CRMP)
Plan sectionRecord requiredOwner
System and intended useAgreed safety contextSystem owner
Risk management activitiesMethods and review pointsAppointed CSO
GovernanceEscalation and approval routesAuthorised client owners

Illustrative output

Clinical Risk Management Plan (CRMP)

Planning and ownership

Illustrative plan structure, not a completed compliance document. Evidence and approval arrangements are agreed for the applicable standard and scope.

What it helps you see

  • Scope
  • Method
  • Review points
  • Responsibilities

Likely format

Clinical Safety Case Report (CSCR)Illustrative structure
Clinical Safety Case Report (CSCR)Illustrative data — not client data
Illustrative Clinical Safety Case Report (CSCR)
Report sectionSupporting evidenceReview
Scope and assumptionsSystem version and intended useConfirm context
Hazards and controlsHazard log and verification recordsClinical review
Residual risks and limitationsDecision and escalation recordsAuthorised risk acceptance

Illustrative output

Clinical Safety Case Report (CSCR)

Safety argument and review

Illustrative report structure. Clinical review follows the documented mandate; authorised client decision-makers retain risk acceptance and deployment authority.

What it helps you see

  • System scope
  • Evidence
  • Residual risks
  • Approval routes

Likely format

Clinical hazard logIllustrative structure
Clinical hazard logIllustrative data — not client data
Illustrative Clinical hazard log
HazardControlOwnerResidual risk
Hazard AControl specified and testedClinical leadAcceptable
Hazard BControl proposed, not evidencedProduct leadUnder review
Hazard CControl owned by deploying organisationDeployment leadTransferred

Illustrative output

Clinical hazard log

Hazard traceability

Hazards linked to causes, controls, owners, residual risk and verification evidence.

What it helps you see

  • Each hazard
  • Cause and control
  • Owner
  • Residual risk

Likely format

Control traceability matrixIllustrative structure
Control traceability matrixIllustrative data — not client data
Illustrative Control traceability matrix
RequirementHazardEvidenceStatus
Requirement AHazard ATest recordVerified
Requirement BHazard BPendingOpen
Requirement CHazard CSupplier evidenceUnder review

Illustrative output

Control traceability matrix

Safety requirements

Every safety requirement traced to a hazard and verification evidence.

What it helps you see

  • Safety requirement
  • Linked hazard
  • Verification evidence
  • Status

Likely format

Change-impact assessmentIllustrative structure
Change-impact assessmentIllustrative data — not client data
Illustrative Change-impact assessment
ChangeImpactNew hazardsDecision
Change ANone—Proceed
Change BWorkflow altered1Conditions set
Change CNew intended use2Safety case update

Illustrative output

Change-impact assessment

Release safety

Whether a release or change alters the clinical risk profile.

What it helps you see

  • Change
  • Clinical risk impact
  • New hazards
  • Decision

Likely format

Illustrative structure — not a client document. Exact outputs and formats depend on the agreed scope.

Scope boundaries

What IG-Smart does — and what stays with your organisation

Agreed consultancy activities

  • Support clinical risk management within the agreed scope
  • Draft or review clinical safety artefacts
  • Coordinate product, clinical and technical stakeholders
  • Provide independent assurance only where competence, objectivity and independence allow

Responsibilities, limits and separately scoped services

  • No guarantee of procurement acceptance, regulatory approval or a harm-free system
  • Your statutory, regulatory, clinical and operational accountability remains with you
  • Clinical review follows the documented CSO mandate; authorised organisational decision-makers retain risk acceptance and release or deployment authority
  • A named CSO appointment is included only where expressly agreed in writing
  • Legal advice, medical-device conformity assessment and product, penetration or accessibility testing are not included in consultancy unless separately agreed with appropriate specialists
  • Your own clinical governance and incident-management responsibilities
  • No independent assurance over work for which IG-Smart held delivery or management responsibility

Scope, deliverables and assumptions are agreed in writing before work begins.

Relevant evidence

Related NHS and HealthTech evidence

Selected published engagements show relevant governance, assurance and NHS/HealthTech capability. They are not presented as clinical safety engagements unless the approved case evidence expressly says so.

  • Named client · Technology / SaaS / RegTech

    Clini-Hub

    Embedded governance and clinical-safety support since start-up

    NHS AI Toolkit, DSPT, DTAC and clinical-safety governance from start-up

    View the evidence: Clini-Hub
  • Named client · Technology / SaaS / RegTech

    accurx

    Retained DPO and NHS IG support

    Retained DPO services · privacy and NHS information-governance support during growth

    View the evidence: accurx
  • Named client · Higher Education / Research

    UCL

    IG audit, improvement plan, training and physical-security audit

    Helped shape and focus the final DSPT submission

    View the evidence: UCL
  • Named client · Healthcare / NHS

    NHS England

    Strategic data-privacy and data-sharing advisory

    National privacy-by-design framework · multiple national workstreams

    View the evidence: NHS England

Your IG-Smart team

Specialist expertise, coordinated around your requirement

Subject-matter expertise is paired with a clear client and programme contact from initial scoping through delivery.

  • Clinical Safety Officer and health informatics specialist

    Himanshu Desai

    MSc, MBA, MRPharmS

    Specialist expertise in health informatics, prescribing and medication-management systems. Has attended NHS England’s Digital Clinical Safety – Practitioner course; his certificate of attendance is available on request.

    View profile
  • Service lead — clinical safety governance and multidisciplinary assurance

    Michael Abtar

    LLB (Hons), PG.Dip.Law, Cert. DPO

    Leads the service, drawing on his experience as Clinical Safety Officer at Royal Brompton & Harefield and coordinating clinical safety with information governance, privacy, cyber assurance and organisational accountability.

    View profile
  • Client & programme contact

    Julia Andrade

    BA

    Coordinates scope, practitioners, delivery and stakeholder communication.

    View profile

Practitioner credentials

Himanshu Desai MSc, MBA, MRPharmS

Himanshu Desai attended NHS England’s Digital Clinical Safety – Practitioner course. His certificate of attendance is available on request.

Clinical safety training
Digital Clinical Safety – Practitioner
Provider
NHS England
Evidence
Certificate of attendance signed by the Clinical Director for Patient Safety; available upon request

Course attendance is training, not a separate professional certification. Professional membership and postnominals do not establish current statutory registration or appointment eligibility; training does not imply NHS endorsement of IG-Smart.

Request Clinical Safety Training Evidence

Service lead experience

Clinical safety experience at Royal Brompton & Harefield

Service lead Michael Abtar’s experience includes serving as Clinical Safety Officer for Royal Brompton & Harefield NHS Foundation Trust. Explore the documented role and engagement context in the related case study.

Read the RBHT Case Study

Clinical governance and healthcare expertise

Himanshu Desai is a registered pharmacist, as confirmed by IG-Smart. His published qualifications include MSc Health Informatics, UCL and MBA, Aston Business School. MRPharmS denotes Royal Pharmaceutical Society membership, not a registration number. Current eligibility, availability and the mandate are checked before any CSO appointment.

Julia Andrade coordinates clients, practitioners and programme delivery; she is not a doctor and is not presented as the clinical decision-maker.

For the approved engagement scope and attributed client account, see Clini-Hub AI HealthTech governance. This is not a claim of NHS approval, certification or procurement success.

DCB0129 vs DCB0160 accountability guide and PDF

After the assessment

Your next step, if further support is needed

Where clinical safety leadership or continuing support is needed, agree a separate CSO appointment or support for your existing CSO as the product or deployment changes.

Further services are optional and separately scoped. Assessment, remediation, implementation and managed support are distinct from independent assurance; independent assurance cannot cover work for which IG-Smart held delivery or management responsibility.

Buyer decisions

Questions before you engage

What evidence supports DCB0129 and DCB0160 requirements?

Core evidence includes a Clinical Risk Management Plan, Hazard Log and Clinical Safety Case Report. Defensible evidence connects intended use, users, workflows, hazards, causes, controls, owners, residual risks and verification evidence. Applicability, depth, review and approval arrangements depend on the system, the applicable standard and the organisation's role. Scope and responsibilities are agreed before work begins.

Who reviews clinical safety evidence and accepts residual risk?

Clinical review follows the applicable standard and documented Clinical Safety Officer mandate. Authorised organisational decision-makers retain risk acceptance and release or deployment authority. IG-Smart can facilitate, draft, review and challenge evidence, but preparing a report or hazard log does not transfer statutory, clinical, operational or governance responsibilities.

Do all digital health products require DCB0129 or DCB0160?

Applicability depends on the system, intended use, organisational role, deployment context and potential effect on patient safety. Not every supplier is subject to both standards. An early applicability and scoping review helps establish the responsibilities and proportionate evidence needed.

What qualifications should a Clinical Safety Officer have?

NHS guidance describes a CSO as a suitably qualified senior clinician with current professional registration and relevant risk management experience. The person should also be appropriately trained for the clinical safety role and able to exercise sound professional judgement. Suitability, current eligibility, availability and the documented mandate are checked before appointment; course attendance and membership alone do not establish eligibility.

Can you review evidence prepared by another supplier or consultancy?

Yes, where competence, objectivity and independence allow. We can review evidence quality and traceability, identify material gaps and recommend proportionate remediation. Independent assurance cannot cover work for which IG-Smart held delivery or management responsibility. The review does not transfer evidence ownership or risk decisions.

Can you support AI-enabled or software-as-a-medical-device products?

Yes, subject to scope and specialist requirements. Clinical safety should be coordinated with AI governance, data protection, cyber security and medical-device responsibilities, rather than treated as a standalone workstream. Consultancy does not itself provide medical-device conformity assessment or regulatory approval.

When should clinical safety work begin?

At the start of product design, procurement or deployment. Early involvement makes hazards easier to control and reduces the risk of discovering major safety issues immediately before release or go-live.

What should organisations do during the DCB0129 and DCB0160 review?

NHS England began a national review of both standards in 2026. Continue working to the current published requirements, maintain version-controlled evidence and monitor official updates. A review alone is not a reason to change a safety case or deployment decision. Assess the impact of official changes before making controlled updates; no transition date or procurement outcome is promised.

How is consultancy different from an appointed Clinical Safety Officer service?

Clinical Safety Consultancy covers scoped assessment, evidence development, remediation and deployment support. An appointed CSO service involves a named practitioner with an agreed mandate and documented clinical duties. Appointment provision can form part of consultancy only where expressly agreed in writing. Named appointments or ongoing support alongside an existing CSO are described on Clinical Safety Officer Services. Organisational accountability, risk acceptance and deployment decisions remain with authorised client decision-makers.

Does completing DTAC mean DCB0129 or DCB0160 duties have been met?

No. DTAC includes a clinical safety area, but sits alongside applicable clinical risk management duties rather than replacing them. Suppliers and deploying organisations must consider which standard applies to their system, intended use, role and deployment context. Supplier evidence does not by itself meet a deploying organisation's responsibilities.

Related insight: DSPT, DTAC, DCB0129 and DCB0160: How NHS HealthTech Governance Fits Together

Investment

Defined clinical safety projects from £7,500 + VAT.

Fees depend on clinical risk, system complexity, existing evidence and the support required. Scope, outputs, duties, capacity and fees are agreed in writing before work begins. Onboarding, initial safety-case development and substantial remediation are quoted separately where required. Existing evidence is reviewed and reused where appropriate; focused reviews and complex programmes are scoped individually. CSO appointment provision is included only where expressly agreed, with suitability, eligibility, availability, mandate and terms confirmed.

What organisations should expect

  • Clearer clinical safety accountability across product, clinical, technical and executive teams
  • Earlier identification of hazards before procurement, release or deployment
  • More complete and traceable safety evidence for DCB0129, DCB0160 and DTAC-related scrutiny
  • Better informed risk acceptance and go-live decisions
  • Reduced rework caused by fragmented documentation or late clinical input
  • A reusable clinical safety capability that supports change, monitoring and incident learning
  • Greater confidence for boards, buyers, commissioners and clinical governance reviewers

Procurement or supplier-assurance review?

Visit our Trust Centre

Ready to move forward?

Build clinical safety into every critical decision.

Not sure which service applies? Find the Right Service

  • Still defining your requirement?

    Discuss Your Clinical Safety Project

    Discuss the requirement, risk, scope and the right engagement model with an experienced practitioner.

    Discuss Your Clinical Safety Project
  • Have a defined scope, tender or RFP?

    Request a Clinical Safety Proposal

    Share a defined requirement, RFP, tender, statement of work or existing scope for senior review.

    Request a Clinical Safety Proposal
  • Procurement or supplier assurance

    Prepare for Procurement Review

    Access company, security and assurance information for supplier review, with controlled evidence available on request.

    Open Trust Centre